GlobeNewswire Inc.··NaFoghorn Therapeutics to Showcase Epigenetic Cancer Targets at 2026 AACR Meeting
Foghorn Therapeutics will present preclinical data on SMARCA2 and epigenetic degrader programs at AACR 2026, advancing pipeline with Eli Lilly partnership.
LLYFHTXcancer treatmentAACR Annual Meeting